Registry of Outcomes of Dezawa MuseCells®
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 89
SponsorMuseCell Innovations Pte LTD
About this trial
The goal of this observational study is to learn about the long-term effects of Dezawa MuseCells to treat various diseases.
The Primary Goal: What is the short-term and long- term outcomes of Dezawa Musecells? Participants treated with Dezawa MuseCells as part of their regular medical care and will answer online survey questions about symptoms and clinical outcomes for 5 years.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Received Dezawa MuseCells® as Part of Routine Clinical Care
Patients ( and/or authorized representative) capable of providing informed consent and participating in long-term follow-up.
Willingness to Complete Online Survey Assessments
Participants must have reliable access to email or a mobile device and be willing to complete digital surveys at scheduled intervals over a 5-year period.
Disqualifiers
Not Receive Dezawa MuseCells®-Individuals who have not been treated with Dezawa MuseCells® or received a counterfeit/non-licensed product cannot be included.
Unable or Unwilling to Provide Informed Consent Includes individuals with cognitive impairment who lack a legally authorized representative willing to consent on their behalf.
Inability to Participate in Long-Term Digital Follow-Up
Concurrent Participation in an Interventional Clinical Trial Affecting Outcomes
Trial population
Patients who have undergone treatment with Dezawa MuseCells
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
MuseCell Treatment
Other interventionPatients undergoing treatment with Dezawa MuseCells
Treatment groups
5,000 Participants
are divided into 4 treatment groupsGroup A: Orthopaedic1 intervention
Group B: Longevity1 intervention
Group C: Wound Care1 intervention
Group D: Pain1 intervention
Trial outcomes
Primary outcomes
1
Change in Patient Reported Symptom Severity
Change in condition-specific symptom severity following Dezawa MuseCell® administration.
Time frame
Baseline; 1 month; 3 months; 6 months; 12 months; annually through 5 years.Secondary outcomes
1
Incidence of Treatment-Related Adverse Events (AEs)
Occurrence, severity, and relatedness of any reported adverse events following Dezawa MuseCell® exposure
Time frame
Baseline through 5 yearsOther outcomes
1
Long-Term Functional Improvement
Evaluation of functional capacity and daily activity performance using validated instruments appropriate to the underlying disease
Time frame
Baseline; 1 month; 3 months; 6 months; 12 months; annually through 5 years.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov